ALDH1A3 and prostate adenocarcinoma: By analyzing the expression levels of the ALDH1A3 gene in PRAD patients of different ages receiving radiotherapy, the results showed that the expression of ALDH1A3 was higher in patients under 60 years old, while the expression was lower in patients 60 years old and above, with statistically significant differences between the two (Figure 4A).